Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

Shu Wang,1 Tao Xue,1 Ruoyu Ma,1 Lin Shi,1 Guanyu Zhu,1 Yin Jiang,2,3 Anchao Yang,1 Fangang Meng,1– 3 Jianguo Zhang1– 3 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Beijing Key Laboratory of Neurostimulation, Beijing, People’s Republic of ChinaCorrespondence: Jianguo Zhang, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email [email protected] Shu Wang, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email [email protected]: Subthalamic deep brain stimulation (STN-DBS) has emerged for Parkinson’s disease (PD), but its long-term effects on levodopa-induced dyskinesia (LID) remain poorly understood.Objective: To assess the long-term LID outcomes and prognostic factors of STN-DBS.Methods: A single-blind longitudinal cohort study was conducted in evaluating 84 PD patients with LID (mean age 61.89 years; 46.4% female; mean disease duration 10.30 years; and mean baseline levodopa-equivalent dose 854.16 mg/day) who underwent STN-DBS at Beijing Tiantan Hospital, Capital Medical University between 2019 and 2021. Assessments at baseline, 1-year (short-term), and 3-year (long-term) regarding motor symptoms, quality of life, neuropsychological status, and cognitive function were analyzed. Primary outcomes focused on LID symptoms (Unified Dyskinesia Rating Scale [UDysRS]). Multivariable linear regression identified prognostic factors.Results: At 1-year, the UDysRS score improved significantly (74.4% reduction, P